SR One Capital Management, LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), SR One Capital Management, LP reported 11 stock positions worth $410.1 million. Its top holding was Arcellx (ACLX) at 43.9% of the portfolio, followed by Ars Pharmaceuticals (SPRY, 10.3%) and Crispr Therapeutics (CRSP, 10.1%). Compared with Q3 2024, it added to 2. The biggest buy was Kala Bio (KALA, shares +35%).
- Most Recent 13F
- Q2 2026
- Location
- Redwood City, CA
- CIK
- 0001910264
- Portfolio Value
- $410.1M (Q4 2024)
- SEC Filing
- 0000950123-25-002049 ↗ filed Feb 13, 2025
Holdings Value
Holdings 11 stocks · $410.1M
| ACLX Arcellx Inc. | 43.88% | 2,346,630 | $180.0M | No change |
| SPRY Ars Pharmaceuticals Inc. | 10.32% | 4,012,903 | $42.3M | No change |
| CRSP Crispr Therapeutics AG | 10.07% | 1,048,951 | $41.3M | No change |
| DSGN Design Therapeutics Inc. | 9.82% | 6,526,476 | $40.3M | No change |
| ZBIO Zenas Biopharma Inc. | 9.81% | 4,911,539 | $40.2M | No change |
| MLYS Mineralys Therapeutics Inc. | 6.05% | 2,016,822 | $24.8M | No change |
| ALMS Alumis Inc. | 3.76% | 1,959,896 | $15.4M | No change |
| ORKA Oruka Therapeutics Inc. | 2.03% | 430,330 | $8.3M | Add +14.7% |
| NKTX Nkarta Inc. | 2.02% | 3,333,333 | $8.3M | No change |
| ENGN Engene Holdings Inc. | 1.21% | 747,750 | $5.0M | No change |
| KALA Kala Bio Inc. | 1.01% | 598,940 | $4.2M | Add +35.0% |
Portfolio Sells Q3 2024 → Q4 2024
| None this quarter. | |||
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $1.0B | MANE, ZBIO, CRSP, AVLN, DSGN |
| Q1 2026 | 14 | $915.4M | ACLX, MANE, ZBIO, CRSP, DSGN |
| Q4 2025 | 13 | $706.4M | ZBIO, ACLX, CRSP, DSGN, MLYS |
| Q3 2025 | 12 | $691.4M | ACLX, CRSP, ZBIO, MLYS, ORIC |
| Q2 2025 | 13 | $461.4M | ACLX, SPRY, CRSP, ZBIO, ORIC |
| Q1 2025 | 12 | $389.3M | ACLX, SPRY, MLYS, ZBIO, CRSP |
| Q4 2024 | 11 | $410.1M | ACLX, SPRY, CRSP, DSGN, ZBIO |
| Q3 2024 | 11 | $498.7M | ACLX, ZBIO, SPRY, CRSP, DSGN |
| Q2 2024 | 9 | $319.4M | ACLX, CRSP, SPRY, ALMS, MLYS |
| Q1 2024 | 6 | $364.1M | ACLX, CRSP, SPRY, NKTX, DSGN |